SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Marcela TOMÍŠKOVÁ, Lenka JAKUBÍKOVÁ, Jana ŠPELDOVÁ, Bohdan KADLEC, Ondřej VENCLÍČEK, Monika BRATOVÁ, Andrea BENEJOVÁ and Zdeněk MERTA. Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno (Treatment with bevacizumab in combination with carboplatin and oral vinorelbine in patients with non-small cell lung cancer (NSCLC) at the Department of Pulmonary Diseases and TB, Masaryk University Faculty of Medicine and University Hospital, Brno). Studia pneumologica et phthiseologica. Praha: Trios s.r.o., 2019, vol. 79, No 3, p. 88-94. ISSN 1213-810X. |
Other formats:
BibTeX
LaTeX
RIS
@article{1555856, author = {Skřičková, Jana and Chloupková, Renata and Tomíšková, Marcela and Jakubíková, Lenka and Špeldová, Jana and Kadlec, Bohdan and Venclíček, Ondřej and Bratová, Monika and Benejová, Andrea and Merta, Zdeněk}, article_location = {Praha}, article_number = {3}, keywords = {Advanced non-small cell lung cancer; Bevacizumab; Carboplatin; Oral vinorelbine; Treatment}, language = {cze}, issn = {1213-810X}, journal = {Studia pneumologica et phthiseologica}, title = {Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno}, url = {https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d}, volume = {79}, year = {2019} }
TY - JOUR ID - 1555856 AU - Skřičková, Jana - Chloupková, Renata - Tomíšková, Marcela - Jakubíková, Lenka - Špeldová, Jana - Kadlec, Bohdan - Venclíček, Ondřej - Bratová, Monika - Benejová, Andrea - Merta, Zdeněk PY - 2019 TI - Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno JF - Studia pneumologica et phthiseologica VL - 79 IS - 3 SP - 88-94 EP - 88-94 PB - Trios s.r.o. SN - 1213810X KW - Advanced non-small cell lung cancer KW - Bevacizumab KW - Carboplatin KW - Oral vinorelbine KW - Treatment UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d L2 - https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d N2 - For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated. ER -
SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Marcela TOMÍŠKOVÁ, Lenka JAKUBÍKOVÁ, Jana ŠPELDOVÁ, Bohdan KADLEC, Ondřej VENCLÍČEK, Monika BRATOVÁ, Andrea BENEJOVÁ and Zdeněk MERTA. Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno (Treatment with bevacizumab in combination with carboplatin and oral vinorelbine in patients with non-small cell lung cancer (NSCLC) at the Department of Pulmonary Diseases and TB, Masaryk University Faculty of Medicine and University Hospital, Brno). \textit{Studia pneumologica et phthiseologica}. Praha: Trios s.r.o., 2019, vol.~79, No~3, p.~88-94. ISSN~1213-810X.
|